Yemchenko Ya. O., Ischeikin K.Ye., Kaidashev I. P.

CLINICAL AND EXPERIMENTAL MEDICINE

Scentific article

Abstract. Psoriasis is a chronic, genetically determined autoimmune polyetiological inflammatory disease with a disorder of epidermal proliferation, provoked by exogenous and endogenous factors, and is characterized by erythema, scaly elements, papules and plaques. According to the results of clinical and epidemiological studies, about 3-4% of the population of our planet suffer from psoriasis, regardless of gender, age and ethnic group, while the proportion of this pathology in the general structure of skin diseases reaches, according to different authors, from 1% to 40%. However, despite the widespread of psoriasis and the research on this problem, there is still no unified view of the pathogenesis of this dermatosis. Therefore, in research of the pathogenesis of psoriasis in recent years more attention is paid to disorder of metabolic processes and obesity. Recently, an indisputable link between psoriasis and obesity has been proven. Obesity has been found to increase the risk of many diseases, including psoriasis. The literature has broadly covered the issue of identical pathogenetic mechanisms of inflammatory processes in psoriasis and obesity, which form a vicious circle at the level of the immune system, which must be broken in order to successfully treat these diseases. In this study, we studied the clinical picture of the disease, and measured anthropometric indicators, determined the degree of obesity by body mass index, analyzed the history of life and disease, and conducted studies of clinical and biochemical blood tests. According to the results of the study, it was revealed that alimentary obesity in patients with psoriasis leads to metabolic disorders complicating the course of dermatosis, which leads to a deterioration in the patient’s dermatological quality of life index, inefficiency of standard methods of therapy and frequent exacerbations of psoriatic disease. Therefore, a more in-depth study of the comorbidity of psoriatic disease will reveal new targets for the treatment of this dermatosis to prevent complicated and more effective treatment of this pathology.

psoriasis, alimentary obesity, pathogenesis, clinic.

1. Valdimarsson H, Thorleifsdottir RH, Sigurdardottir SL. Psoriasis – as an autoimmune disease caused by the molecular mimicry. Trends in Immunology. 2019;30(10):494-501.
2. Yemchenko YaO. Osobennosti klinicheskogo techeniya psoriaza u bol’nyh s soputstvuyuschim metabolicheskim sindromom v zavisimosti ot urovnya sistemnogo vospaleniya. Georgian Medical News. 2014;11(236):43-47. [in Russian].
3. Razina AO, Achkasov EE, Runenko SD. Ozhirenie: sovremennyiy vzglyad na problemu. Ozhirenie i metabolizm. 2016;13(1):3–8. [in Russian].
4. Atkinson RL. Could viruses contribute to the worldwide epidemic of obesity? Int J Pediat Obes. 2018;3(1):37-43.
5. Kaydashev IP. Izmenenie obraza zhizni, narushenie energeticheskogo metabolizma i sistemnoe vospalenie kak faktory razvitiya bolezney civilizacii. Ukraїns’kiy medichniy chasopis. 2013;5:103-108. [in Ukrainian].
6. Babak OYa, Yarmish NV, Shkol’nik VV. Ozhirіnnya yak puskoviy mehanіzm adipocitokіnovogo kaskadu. Medicina transportu Ukrainy. 2012;2:94-99. [in Ukrainian].
7. Yemchenko YaO. Ozhyrinnia yak komorbidnyi stan pry psoriazi. Vіsnik ukrains’koi medich stomat akademіi. 2018;18(63):314-319. [in Ukrainian].
8. National Institutes of Health (NIH), National Heart, Lung, and Blood Institute (NHLBI). The practical guide: Identification, Evaluation, and Treatment of Overweight and Obesity in Adults [Internet]. USА: Department of Health and Human Services; 2000. Available from: https:// www.nhlbi.nih. gov/files/docs/ guidelines/prctgd_c.pdf.
9. Basra MK, Fenech R, Gatt RM, Salek MS and Finlay AY. The Dermatology Life Quality Index 1994-2007: a comprehensive review of validation data and clinical results. Br J Dermatol 2008;159:997-1035.
10. Fredriksson T, Pettersson U. Severe psoriasis – oral therapy with a new retinoid. Dermatologica, 1978;157(4):238-44.
11. Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA. 2001;285(19):2486-2497.
12. Morris PB, Ballantyne CM, Birtcher KK, Dunn SP, Urbina EM. Review of clinical practice guidelines for the management of LDL-related risk. J Am. Coll. Cardiol. 2014;64:196–206.
13. Babak OYA, Yarmish NV, Shkol’nik VV. Ozhirіnnya yak puskoviy mehanіzm adipocitokіnovogo kaskadu. Medic transp Ukrainy. 2012;2:94- 99. [in Ukrainian].
14. Mitsui A, Tada Y, Takahashi T, Shibata S, Kamata M. Serum IL-33 levels are increased in patients with psoriasis. Experim dermatol. 2015;3(2):234-239.
15. Kaydashev IP. NF-kB activation as the molecular basis of pathological process by metabolic syndrome. Fiziol. Zhurn. 2012;58(1):93-101.
16. Kamylov FKh, Mufazalova NA, Kapuler OM. Tsytokinovyi dysbalans v ymmunopatoheneze psoriaza. Fundamentalni doslidzhennia. 2015;1(5):1065-1071. [in Russian].
17. Clark RA. Resident memory T cells in human health and disease. Science Translation Medicine. 2015;7(269):269-274.
18. Cosmi L, Liotta F, Maggi E. Th17 and non-classic Th1 cells in chronic inflammatory disorders: two sides of the same coin. International Archives of Allergy and Immunology. 2014;164(3):171-177.
19. Bertheloot D, Latz E. HMGB1, IL-1a, IL-33 and S100 proteins: dual-function alarmins. Nature. 2017;14(1):43-64.
20. Martinez FO, Gordon S. The M1 and M2 paradigm of macrophage activation: time for reassessment. F1000Prime Rep. 2014;3:13-18.

«Bulletin of problems biology and medicine» Issue 1 (159), 2021 year, 53-57 pages, index UDK 616.517-056.5

10.29254/2077-4214-2021-1-159-53-57